NCT07338071

Brief Summary

"Antithrombotic Therapy at the End of Life: The PEACE Study" is a multicenter, non-profit, cross-sectional observational study. In the absence of shared guidelines, therapeutic decisions on antithrombotic drugs vary significantly according to healthcare professional training and national context, resulting in marked variability in prescribing practices. This study aims to describe the prevalence of antithrombotic prescriptions in patients referred to Palliative Care.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
410

participants targeted

Target at P75+ for all trials

Timeline
18mo left

Started Jan 2026

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress19%
Jan 2026Nov 2027

Study Start

First participant enrolled

January 1, 2026

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

January 3, 2026

Completed
10 days until next milestone

First Posted

Study publicly available on registry

January 13, 2026

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2027

Last Updated

January 13, 2026

Status Verified

December 1, 2025

Enrollment Period

1.8 years

First QC Date

January 3, 2026

Last Update Submit

January 3, 2026

Conditions

Palliative Care

Keywords

antithrombotic therapyend of lifepalliative care

Outcome Measures

Primary Outcomes (1)

  • Prevalence of antithrombotic drug use

    Calculation of the prevalence of antithrombotic drug use in hospitalized patients referred to Palliative Care pathway.

    at enrollment

Interventions

antithrombotic drugsDRUG

use of antithrombotic drug

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study sample will consist of hospitalized patients referred to a Palliative Care pathway

You may qualify if:

  • Adults (≥18 years) hospitalized and referred to Palliative Care (home-based or residential) at the discretion of the attending physician.
  • Signed informed consent

You may not qualify if:

  • none

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Roma, RM, 00168, Italy

Location

MeSH Terms

Conditions

Death

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

Roberto Pola

CONTACT

+390630157075roberto.pola@policlinicogemelli.it

Rosa Talerico

CONTACT

+390630157075rosa.talerico@unicatt.it

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof.

Study Record Dates

First Submitted

January 3, 2026

First Posted

January 13, 2026

Study Start

January 1, 2026

Primary Completion (Estimated)

November 1, 2027

Study Completion (Estimated)

November 1, 2027

Last Updated

January 13, 2026

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will not share

Locations

IT(1)